越秀交通基建(01052.HK):10月除廣西蒼郁高速、湖北隨岳南高速項目外路費收入按年下降
越秀交通基建(01052.HK)公布,10月起全國多地發生本土疫情。受此影響,全國各地高速公路車流量和路費收入整體大幅下降;此外,國務院常務會議確定的本年度第四季度將收費公路貨車通行費減免10%的政策,也從當月開始實施。受上述因素影響,集團除廣西蒼郁高速、湖北隨岳南高速項目外,其餘項目路費收入均按年下降。
當中,廣州北二環高速:當月收費車流量、路費收入按月下降29.6%、25.7%。當月收費車流量、路費收入按年下降21.2%、22.2%,主要是由於廣州市持續發生疫情,導致車流量減少;廣佛肇高速(廣州段)新建成的朝陽互通立交於1月16日正式通車,持續對本路段造成了分流影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.